Need help finding what you are looking for?
Contact Us
PUBLISHER: Coherent Market Insights | PRODUCT CODE: 2051426
PUBLISHER: Coherent Market Insights | PRODUCT CODE: 2051426
Spinal Muscular Atrophy Market, by Type, by Treatment, by Age Group, by Route of Administration, by Distribution Channel, By Geography
PUBLISHED:
PAGES: 156 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
Spinal Muscular Atrophy Market is estimated to be valued at USD 2,295.5 Mn in 2026 and is expected to reach USD 5,638.9 Mn by 2033, growing at a compound annual growth rate (CAGR) of 13.7% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 2,295.5 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 13.70% | 2033 Value Projection: | USD 5,638.9 Mn |
Spinal muscular atrophy (SMA) is a genetic disease that affects the peripheral nervous system, central nervous system, and voluntary muscle movement (skeletal muscle). SMA is muscular since it primarily affects muscles, which do not receive impulses from the nerve cells. Atrophy is the medical term for shrinking, which is what muscles do when they are not stimulated by nerve cells. SMA is a motor neuron disease that includes the loss of nerve cells termed motor neurons in the spinal cord. It mostly affects infants and children but can also develop in adults. An individual with SMA inherits two copies of a faulty (mutated) or missing survival motor neuron 1 (SMN1) gene.
Market Dynamics
The increasing product launches by the key players in the market are expected to drive the market growth over the forecast period. For instance, in August 2022, Chugai Pharmaceutical Co., Ltd., a drug manufacturer operating in Japan, announced that it had launched Evrysdi Dry Syrup 60 mg (generic name: risdiplam) for the treatment of spinal muscular atrophy (SMA).
Moreover, the increasing adoption of inorganic strategies such as partnerships and collaborations by the key players is expected to drive the market growth over the forecast period. For instance, in March 2022, the Spinal Muscular Atrophy Foundation, the leading funder of SMA research worldwide, and PTC Therapeutics, Inc., a U.S. based pharmaceutical company, entered into a new collaboration focused on developing new treatments and regenerative medicine to further advance scientific research in SMA and other neuromuscular disorders.
Key features of the study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global spinal muscular atrophy market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Biogen, CYTOKINETICS, Hoffmann-La Roche Ltd, Genentech, Inc., PTC Therapeutics, Inc., Novartis AG, Ionis Pharmaceuticals, Chugai Pharmaceutical Co., Ltd., NMD PHARMA A/S, and Astellas Pharma Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global spinal muscular atrophy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts1
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global spinal muscular atrophy market
Market Segmentation
- Global Spinal Muscular Atrophy Market, By Type (Revenue, USD Mn, 2021 - 2033)
- Type I
- Type II
- Type III
- Type IV
- Global Spinal Muscular Atrophy Market, By Treatment (Revenue, USD Mn, 2021 - 2033)
- Gene Therapy
- Disease-modifying drugs
- Global Spinal Muscular Atrophy Market, By Age Group (Revenue, USD Mn, 2021 - 2033)
- Infant
- Adult
- Global Spinal Muscular Atrophy Market, By Route of Administration (Revenue, USD Mn, 2021 - 2033)
- Oral
- Injectables
- Global Spinal Muscular Atrophy Market, By Distribution Channel (Revenue, USD Mn, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Spinal Muscular Atrophy Market, By Region (Revenue, USD Mn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Company Profiles
- Biogen, CYTOKINETICS
- F. Hoffmann-La Roche Ltd
- Genentech, Inc.
- PTC Therapeutics, Inc.
- Novartis AG
- Ionis Pharmaceuticals
- Chugai Pharmaceutical Co., Ltd.
- NMD PHARMA A/S
- Astellas Pharma Inc.
Product Code: CMI1920
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Type
- Market Snapshot, By Treatment
- Market Snapshot, By Age Group
- Market Snapshot, By Route of Administration
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Market Trends
- Acquisitions and Partnerships Scenario
- Technological Advancements
- Regulatory Scenario
- PEST Analysis
- Product Launches
4. Global Spinal Muscular Atrophy Market, By Type, 2021 - 2033, (US$ Million)
- Overview
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Type I
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
- Type II
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
- Type III
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
- Type IV
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
5. Global Spinal Muscular Atrophy Market, By Treatment, 2021 - 2033, (US$ Million)
- Overview
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Gene Therapy
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
- Disease-modifying drugs
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
6. Global Spinal Muscular Atrophy Market, By Age Group, 2021 - 2033, (US$ Million)
- Overview
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Infant
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
- Adult
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
7. Global Spinal Muscular Atrophy Market, By Route of Administration, 2021 - 2033, (US$ Million)
- Overview
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Oral
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
- Injectables
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
8. Global Spinal Muscular Atrophy Market, By Distribution Channel, 2021 - 2033, (US$ Million)
- Overview
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Hospital Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
- Retail Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
- Online Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
9. Global Spinal Muscular Atrophy Market, By Region, 2021 - 2033, (US$ Million)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2021 - 2033
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Age, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Age, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Age, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
- UK
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Age, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Age, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Age, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 - 2033, (US$ Million)
- North Africa
- Central Africa
- South Africa
10. Competitive Landscape
- Biogen
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- CYTOKINETICS
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- F. Hoffmann-La Roche Ltd
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Genentech, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- PTC Therapeutics, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Ionis Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Chugai Pharmaceutical Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- NMD PHARMA A/S
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Astellas Pharma Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
11. Analyst Recommendation
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
12. Section
- References
- Research Methodology
- About Us and Sales Contact
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.